Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 Combined With Temozolomide in Advanced Melanoma
NCT05106023Phase 2Unknown
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in melanoma. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05106023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106023.